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Abstract Genotoxic stress causes proliferating cells to activate the DNA damage checkpoint, to
assist DNA damage recovery by slowing cell cycle progression. Thus, to drive proliferation, cells
must tolerate DNA damage and suppress the checkpoint response. However, the mechanism
underlying this negative regulation of checkpoint activation is still elusive. We show that human
Cyclin-Dependent-Kinases (CDKs) target the RAD9 subunit of the 9-1-1 checkpoint clamp on
Thr292, to modulate DNA damage checkpoint activation. Thr292 phosphorylation on RAD9 creates
a binding site for Polo-Like-Kinase1 (PLK1), which phosphorylates RAD9 on Thr313. These CDK-
PLK1-dependent phosphorylations of RAD9 suppress checkpoint activation, therefore maintaining
high DNA synthesis rates during DNA replication stress. Our results suggest that CDK locally
initiates a PLK1-dependent signaling response that antagonizes the ability of the DNA damage
checkpoint to detect DNA damage. These findings provide a mechanism for the suppression of
DNA damage checkpoint signaling, to promote cell proliferation under genotoxic stress conditions.
DOI: https://doi.org/10.7554/eLife.29953.001
Introduction
To proliferate and maintain the integrity of biological systems, cells possess the ability to overcome
environmental stresses. Genomic DNA damage is a type of environmental stress, and when cells are
exposed to genotoxic stress, cell cycle progression is delayed by a mechanism called the DNA dam-
age checkpoint. Although the delay increases the time available for DNA repair processes to per-
form damage recovery (Elledge, 1996; Weinert and Hartwell, 1988), the degree of the checkpoint
response must be tightly regulated, depending on the proliferative status of the cells. Notably, if
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cells must proliferate, then the checkpoint response should be down-regulated to tolerate the cellu-
lar DNA damage stresses. This may be accomplished via the interplay between the pro-mitotic activ-
ity and the DNA damage checkpoint in the cell, although the precise mechanism remains enigmatic
(Serrano and D’Amours, 2014).
Among the pro-mitotic activities, CDKs are the primary driving forces that order and coordinate
cell cycle events (Swaffer et al., 2016). Activation by CDKs not only initiates M-phase events, but
also controls temporally ordered programs throughout the cell cycle, such as replication origin firing
upon initiation of DNA replication, which potentially support proliferation (Stern and Nurse, 1996;
Tanaka et al., 2007; Trovesi et al., 2013; Zegerman and Diffley, 2007). However, problems may
arise once DNA replication is initiated. The DNA replication forks can encounter damaged DNA or
environmental stress-mediated nucleotide depletion, and such events can stall replication polymer-
ases at the fork (Jossen and Bermejo, 2013). The stalled replication forks expose single-stranded
DNA, which is recognized by checkpoint signaling complexes that activate the S-phase checkpoint
(Giannattasio and Branzei, 2017; Katou et al., 2003; Sogo et al., 2002; Zou and Elledge, 2003;
Zou et al., 2003). When the DNA damage response is dominant, checkpoint signaling reduces the
rate of S-phase progression by repressing late origin firing or by slowing the progression of individ-
ual replication forks. Together, these events can reduce genomic instability in proliferating cells, and
thereby provide tumor-suppressor functions (Iyer and Rhind, 2013; Zegerman and Diffley, 2009).
Interestingly, under some circumstances, pro-mitotic activity dominates DNA damage checkpoint
signaling, and cells commence proliferation even in the presence of damaged DNA. The key protein
involved in the pro-mitotic activity to override DNA damage checkpoint signaling is PLK1. This phe-
nomenon was initially reported as adaptation, and was originally described in a budding yeast sys-
tem in which cells overrode a G2 DNA damage checkpoint via a CDC5 (budding yeast PLK1
orthologue)-dependent mechanism, after prolonged G2 arrest induced by irreparable DNA double-
strand breaks (DSBs) (Pellicioli et al., 2001; Sandell and Zakian, 1993; Toczyski et al., 1997).
Adaptation was also reported in a Xenopus system, in which a prolonged aphidicolin-induced repli-
cation block was compromised by a Plx1 (Xenopus PLK1 orthologue)-dependent process (Yoo et al.,
2004), and an analogous phenomenon has also been reported in mammalian cells. However, mam-
malian cells only activate the G2/M DNA damage checkpoint when a certain amount of DNA dam-
age (e.g. ~20 DSBs) is present. Indeed, mammalian cells can enter mitosis even in the presence of
DNA damage signals, such as g-H2AX foci (Deckbar et al., 2007; Ishikawa et al., 2010;
Syljua˚sen et al., 2006). In this sense, mammalian cells can somehow repress a DNA damage check-
point mechanism to tolerate the DNA damage response in order to drive proliferation, and PLK1
exhibits the key pro-mitotic activity for this purpose. When the cellular PLK1 activity reaches a certain
level, the cells can re-enter mitosis upon recovery from G2 checkpoint arrest (Liang et al., 2014).
However, in the case of the DNA damage checkpoint in S-phase, the crosstalk between PLK1 and
the DNA damage response becomes more complicated. In fact, PLK1 functions not only upon
mitotic commitment, but also during S phase or a related DNA damage response, thereby facilitat-
ing DNA metabolism in support of rapid cell proliferation (Moudry et al., 2016; Yata et al., 2012).
Importantly, the PLK1 protein contains a Polo-Box Domain (PBD) that recognizes a pre-phosphory-
lated substrate (Elia et al., 2003). The substrate is phosphorylated by a kinase, typically a CDK, and
the PBD preferentially recognizes phospho-serine/threonine (-S-pS/pT-P-)-containing peptides
(van Vugt et al., 2010).
In this study, to clarify how proliferating cells override the DNA damage checkpoint in S-phase,
we revisited the CDK-dependent phosphorylation in the checkpoint processes, using human cells.
We found that CDK targeted RAD9, a subunit of the DNA clamp complex 9-1-1, which acts as a
DNA damage sensor protein complex in checkpoint signaling (Delacroix et al., 2007; Furuya et al.,
2004; Kumagai et al., 2004; Lee et al., 2007; Liu et al., 2012; Navadgi-Patil and Burgers, 2009;
St Onge et al., 2003; Takeishi et al., 2010). If CDK failed to phosphorylate RAD9, then the cells
accumulated in S phase in the presence of low doses of hydroxyurea (HU). The CDK-dependent
phosphorylation of RAD9 at residue 292 (pThr292) created a binding site for PLK1, and the bound
PLK1 was then activated to further phosphorylate RAD9 on Thr313 and Ser326. We also found that
these CDK- and PLK1-dependent phosphorylations of RAD9 were required to maintain the rate of
S-phase progression in cells exposed to low-dose HU, and this correlated with the mutant pheno-
type in which increased amounts of active checkpoint complexes accumulated on the damaged chro-
matin. Additionally, mutant RAD9 proteins that could not be phosphorylated by CDK-PLK1 were
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also associated with the damaged chromatin. These results implied that the CDK-/PLK1-dependent
control of DNA damage detection by RAD9 plays a crucial role in minimizing the DNA damage
checkpoint response, thus helping to drive proliferation under conditions of DNA replicative stress.
Results
CDK-dependent phosphorylation of RAD9 at Thr292
To understand how CDK controls the DNA damage checkpoint, we focused on the human check-
point protein RAD9, which forms a PCNA-like hetero-trimeric checkpoint clamp complex. This com-
plex (designated as 9-1-1) functions as a DNA damage sensor by binding to damaged DNA ends
(Caspari et al., 2000; Majka et al., 2006; Thelen et al., 1999), and this function must be precisely
regulated to control the degree of checkpoint activation. Indeed, using the fission yeast (Schizosac-
charomyces pombe) system, we previously identified multiple phosphorylation events on the S.
pombe Rad9 homologue (spRad9) that regulate the checkpoint activation and the spRad9 release
from damaged chromatin (Furuya et al., 2010, 2004). In the present study, we focused on Thr292 (-
His-Ser-292Thr-Pro-) of the human RAD9 homologue (Figure 1A), because the residue resembles
Thr321 (-His-Ser-Ser-321Thr-Pro-) of SpRad9, which when phosphorylated promotes the release of
SpRad9 from DNA damage sites.
The phosphorylation of RAD9 Thr292 was originally identified by Davey’s group (St Onge et al.,
2003). As this Thr residue is followed by a proline residue and the region resembles a putative CDK
phosphorylation site, we first tested whether the phosphorylation of Thr292 depended on CDK.
RAD9 with a C-terminal myc-His (mH) tag was transiently expressed in HEK293A cells, and the cell
lysates were subjected to fractionation by centrifugation in sucrose-containing buffer (Figure 1—fig-
ure supplement 1A)(Ohashi et al., 2014; Zou et al., 2002). Western blotting was performed using
an antibody that recognizes phosphorylated Thr292 (pThr292). We detected the pThr292 signal pri-
marily in the supernatant fraction (Figure 1—figure supplement 1A). The pThr292 band corre-
sponded to the uppermost band of the RAD9-myc signal, as previously reported (Figure 1—figure
supplement 1A) (St Onge et al., 2003). The pThr292 signal was diminished in roscovitine (CDK
inhibitor)-treated cells, although the band was still detectable in RO-3306 (CDK1 inhibitor)-treated
cells (Meijer et al., 1997; Vassilev et al., 2006). These results suggested that any CDK would be
able to phosphorylate Thr292 of RAD9. Importantly, the pThr292 signal was diminished when a
mutant RAD9, with Thr292 substituted with alanine (T292A), was expressed in place of wild-type
RAD9 (Figure 1—figure supplement 1A).
We further tested the ability of CDK to phosphorylate RAD9 Thr292 in an in vitro kinase assay,
using a recombinant CDK2-cyclinA2 complex. The C-terminal region of RAD9 (a.a. 266–391) was
fused to GST, purified from E. coli cells by glutathione affinity chromatography, and assayed to
detect CDK-dependent phosphorylation in vitro. pThr292 was detected as efficiently as pSer277 by
western blotting (Figure 1B) (St Onge et al., 2003). We also confirmed that the phosphorylation at
Thr292 was not dependent on other CDK phosphorylation sites (Ser277, Ser328, Ser336) that are
responsible for the major bandshift of GST-RAD9 in vitro (St Onge et al., 2003) (data not shown).
Next, to assess the behavior and effects of the CDK-dependent phosphorylation of RAD9 in vivo,
we constructed stable HEK293A cell lines that harbor a CMV-tetO-RAD9-mH construct (genomically
integrated at the FRT locus) and therefore express wild-type or Thr292-mutated (T292A) RAD9-mH.
For the in vivo cell line experiment, we used RAD9-S291A/T292A in place of RAD9-T292A, and these
two mutant proteins were treated similarly throughout the manuscript. RAD9-mH was expressed
when doxycycline was added to the medium (Figure 1—figure supplement 1B). Although RAD9-
mH was expressed at a level approximately five times higher than endogenous RAD9, we assumed
that this increased level of ectopic expression did not affect the protein’s usual cellular activity. Extra
copies of RAD9 reportedly associate with, and are possibly sequestered by, the CAD (carbamoyl-
phosphate synthetase) protein, which does not associate with RAD1-HUS1 (Lindsey-Boltz et al.,
2004), and thus the expression of the mutant RAD9 would replace the endogenous RAD9 as a com-
ponent of the 9-1-1 complexes.
A thymidine block and release was performed to synchronize the cells in G1/S, and the cell cycle
profile of pThr292 was monitored. After the cells were released from the thymidine-induced G1/S
block, the cells that expressed RAD9-mH from either CMV-tetO-RAD9-mH or CMV-tetO-RAD9-
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Figure 1. CDK phosphorylates threonine 292 of RAD9. (A) Schematic of the aim of this manuscript. (B) The recombinant GST-tagged C-terminal (a.a.
266–391) portion of RAD9 was mixed with the purified active CDK2-CyclinA2 complex. Western blotting was performed using the a-RAD9 antibody and
the a-pT292 (pT292) and a-phospho-Ser277 (pS277) RAD9 antibodies. (C) Top: The thymidine block and release experiment was performed on
HEK293A-T-REx cell lines stably expressing RAD9-WT-mH or RAD9-S291A/T292A-mH. Doxycyclin (0.5 mg/ml) was added during the second thymidine
Figure 1 continued on next page
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S291A/T292A-mH were harvested and subjected to a western blotting analysis, using anti-pThr292
(pT292: Figure 1C). The phosphorylation of Thr292 was observed weakly from mid S phase (6–8 hr
in Figure 1C) and strongly at the G2/M transition, a pattern that correlated with the CDK activity. In
combination with the above results, these experiments confirmed that CDK phosphorylates the
Thr292 residue of RAD9 both in vitro and in vivo.
Checkpoint signaling is enhanced upon RAD9-T292A expression
We observed a slight delay in the mitotic commitment, as detected by the delayed appearance of
the phosphorylation of histone H3 Ser10, in cells expressing T292A-mutated RAD9 (Figure 1C, bot-
tom). This implied a role of the CDK-dependent phosphorylation (pThr 292) in inhibiting the RAD9
activity for the DNA damage checkpoint.
Next, we sought to determine how the CDK-dependent phosphorylation of RAD9 affected the
checkpoint-activating processes at the molecular level. To do so, we monitored the amount of chro-
matin-bound checkpoint proteins in HEK293A-T-REx cells expressing either wild-type or T292A-
mutated RAD9 under replicative stress (1.5 mM hydroxyurea), by performing a fractionation assay
followed by a western blotting analysis (Figure 1D) (Ohashi et al., 2014; Zou et al., 2002). Tubulin
and H2AX were specifically detected in the Triton X-100 soluble (S1) and insoluble (P1/P2) fractions,
respectively, suggesting that the fractionation functioned appropriately. The majority of the RAD9-
myc was found in the S1 fraction, as previously reported, and approximately 10% of the RAD9-myc
was found in the insoluble fraction. The proportion of wild-type RAD9 (WT) in the insoluble fraction
decreased after the cells were exposed to HU (see ‘+HU’ in Figure 1D). In contrast, the T292A-
mutated RAD9 (T292A) remained in the insoluble fraction when the cells were exposed to HU. A
previous report showed that upon the activation of the checkpoint, the 9-1-1 complex is loaded
onto DNA damage sites by the RAD17 clamp loader complex and the DNA damage signal is trans-
mitted to the CHK1 kinase (Zou et al., 2002). Indeed, higher levels of RAD17 and the Ser345-phos-
phorylated CHK1 accumulated in the insoluble fraction of HU-treated cells expressing the T292A-
mutated RAD9 (+HU, compare WT and T292A in Figure 1D). The increased amounts of checkpoint
components in the chromatin fraction suggested that the checkpoint is enhanced in cells expressing
the T292A-mutated RAD9.
S-phase progression is slowed in cells exposed to low-dose HU when
CDK fails to phosphorylate RAD9 Thr292
The enhanced association of RAD9 and phosphorylated CHK1 with chromatin in the presence of HU
suggested the ectopic activation of the intra-S-phase checkpoint, when CDK failed to phosphorylate
RAD9 at Thr292. The intra-S-phase checkpoint is activated when cells are under dNTP-depletion
stress or when replication forks encounter DNA damage (Paulovich and Hartwell, 1995). The activa-
tion of this checkpoint delays the timing of late origin firing, which is a CDK-dependent process
Figure 1 continued
block. The western blotting analysis of cell lysates obtained at the indicated time points is shown, and a-myc, a-pT292 and a-pS277 antibodies were
used. The asterisk (*) shows a nonspecific signal. Bottom: The cell cycle profiles were quantified by a flow cytometer analysis. The G1, S, and G2 phases
were quantified via propidium iodide staining, and the M phase cells were quantified using an antibody against the phospho-serine 10 of histone H3.
(D) A chromatin fractionation assay (Ohashi et al., 2014; Zou et al., 2002) was performed in HEK293A-T-REx cell lines stably expressing RAD9-WT-mH
(WT) or RAD9-S291A/T292A-mH (T292A). Cells were grown in media containing 1.5 mM hydroxyurea for 16 hr (+HU) and then released from the
hydroxyurea arrest for 1 hr (Rel.). A western blotting analysis is shown, and a-RAD17, a-myc (RAD9), a-phospho-serine 345 of CHK1 (CHK1-pS345), a-
phospho-serine 139 of Histone H2AX (p-H2AX), a-H2AX, a-phospho-threonine 68 of CHK2 (CHK2-pT68), and a-tubulin were used. (E) The flow
cytometry analysis was performed with U2OS T-REx cells stably expressing RAD9-WT-mH (WT) or RAD9-S291A/T292A-mH (T292A), and the host U2OS
T-REx cells (Mock). The cells were grown in media containing 0.2 mM hydroxyurea for 24 hr. The populations of cells showing the S phase peaks were
quantified and indicated below the flow cytometer profiles. See also Figure 1—figure supplement 1. CDK phosphorylates threonine 292, and
construction of RAD9-WT or -S291A/T292A(T292A) expressing stable cell lines.
DOI: https://doi.org/10.7554/eLife.29953.002
The following figure supplement is available for figure 1:
Figure supplement 1. CDK phosphorylates threonine 292, and construction of the RAD9-WT and -S291A/T292A(T292A) expressing stable cell lines.
DOI: https://doi.org/10.7554/eLife.29953.003
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(Dimitrova and Gilbert, 2000; Santocanale and Diffley, 1998; Shirahige et al., 1998; Tanaka and
Araki, 2010; Yekezare et al., 2013).
To detect S-phase progression in cells, we used U2OS-T-REx cells stably expressing wild-type
RAD9 or T292A-mutated RAD9 from the FRT locus (Figure 1—figure supplement 1C). We per-
formed these experiments in the presence of 0.2 mM HU, a lower concentration of HU that allowed
the control U2OS cells to grow with a mild S-phase delay. Here, we assessed the cell cycle delay by
flow cytometry, to measure the cellular DNA content (Figure 1E). In the absence of HU, the U2OS
cells that expressed wild-type RAD9 (WT) and those that expressed the T292A-mutated RAD9
(T292A) behaved similarly to the parental U2OS-T-REx cells. However, in presence of 0.2 mM
hydroxyurea, although the cells expressing wild-type RAD9 showed similar profiles to the parental
U2OS cells, the cells expressing the T292A-mutated RAD9 exhibited an increased population of
S-phase cells (Figure 1E, WT: 35.8%, T292A: 43.2%).
The accumulation of S-phase cells could be due to a slower rate of DNA synthesis. Therefore, we
quantified the rate of dNTP incorporation by EdU (ethynyl-deoxy-uridine)-labeling (Salic and Mitchi-
son, 2008). Without HU treatment, both cell lines (expressing wild-type or T292A-mutated RAD9)
showed similar amounts of EdU incorporation during S phase. However, when these cell lines were
treated with 0.2 mM HU for 24 hr, the amount of EdU incorporation in the cells expressing the
T292A-mutated RAD9 was reduced to 60–70% of that in the HU-exposed cells expressing wild-type
RAD9 (details shown later in Figure 4B, compare WT and T292A). This result suggested that the
higher rate of genomic DNA replication under dNTP depletion stress was maintained through the
CDK-dependent phosphorylation of Thr292 of RAD9.
PLK1 binds to, and is activated by, the phosphorylated Thr292 of RAD9
Next, we explored the biochemical consequences of the CDK-dependent phosphorylation of Thr292
(pThr292) of RAD9. We noticed that the peptide sequence around pThr292 (289-Ala-His-Ser-pThr-
Pro-293) resembles the cognate sequence for PLK1 binding (Elia et al., 2003). PLK1 is a kinase with
a C-terminal phospho-peptide-recognizing motif called the PBD, which is known to bind to a Ser-
pSer/pThr-Pro consensus motif. Indeed, we found that the PBD of PLK1, but not those of PLKs2-5,
efficiently bound to the C-terminus of RAD9 in a yeast two-hybrid assay (Figure 2—figure supple-
ment 1A). We further demonstrated that this binding decreased when Thr292 of RAD9 was substi-
tuted with alanine (Figure 2—figure supplement 1A).
We then performed an in vitro ‘pull-down’ experiment using recombinant GST-RAD9 protein (C-
terminus: a.a. 266–391) and PLK1. In the course of the assay, the GST-RAD9 protein was phosphory-
lated by a recombinant CDK2-cyclinA2 complex. PLK1 co-precipitated efficiently using GSH-beads,
but only when CDK2-cyclinA2 was present (Figure 2A and B). Notably, this experiment employed a
kinase buffer containing ATP, and we observed a bandshift of GST-RAD9 only when PLK1 was pres-
ent (lane three in Figure 2A, lane one in Figure 2B). Consistent with the notion that PLK1 binds to
and phosphorylates pre-phosphorylated substrates, we observed enriched Thr292 phosphorylation
(pT292) in the bandshifted form of GST-RAD9 (Figure 2A). We should also note that hereafter, we
used GST-RAD9 in which S277, S328 and S336 were each substituted with alanine; the resulting
GST-RAD9 (3A) construct facilitated the recognition of PLK1-induced phosphorylation by the band-
shift (Figure 2—figure supplement 1B).
If PLK1 binds to Thr292-phosphorylated RAD9, then the binding should be competed with a
phospho-peptide that contains pThr292. Therefore, we incubated PLK1 and GST-RAD9 together
with various phospho-peptides, and monitored the association of PLK1 with the GSH-bead fraction.
PLK1 remained in the supernatant fraction when incubated with a pThr292-containing peptide
(pT292), but not when incubated with other peptides (Non-P, pS291, pS291/pT292) or in the
absence of a competing peptide (Figure 2C; compare Sup and Beads).
To further confirm the specific interaction between pThr292 and PLK1, we tested whether a
pThr292-containing peptide could activate PLK1. The PBD can reportedly act as an auto-inhibitor of
the PLK1 kinase domain, and the binding of a substrate to the PBD counteracts this auto-inhibitory
function (Jang et al., 2002). Here, we used GST-RAD9 (3A)-T292A (which PLK1 cannot bind) as the
substrate for kinase assays using PLK1 (Figure 2D). The bandshift in the anti-RAD9 western blot was
only observed in the presence of a pThr292-containing peptide, and the use of other peptides in the
reaction did not yield a bandshift (Figure 2D). These data suggested that a pThr292-containing
phospho-peptide binds to and ‘activates’ PLK1, to promote the further phosphorylation of RAD9.
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Figure 2. CDK-dependent phosphorylation of threonine 292 of RAD9 accommodates and activates PLK1. (A) The RAD9 C-terminus co-precipitates with
PLK1. GST-RAD9 (3A: S277A, S328A, S336G) (30 pmol) was pre-incubated with CDK2-Cyclin A2 (0.5 pmol) in 15 ml of kinase buffer at 30 ˚C for 30 min,
followed by an incubation with 4 pmol of PLK1 (30 ˚C for 5 min followed by 4 ˚C for 30 min). The reaction mixture was captured with GSH-beads for 30
min at 4 ˚C. A schematic of the experiment is shown (left). A western blot analysis was performed using a-PLK1 (PLK1) and a-pT292 (pT292) antibodies,
Figure 2 continued on next page
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The association of PLK1 with RAD9 was confirmed by the cell line experiments. Using anti-myc-
coated agarose beads, co-immunoprecipitation (co-IP) experiments were performed using cell
lysates from the RAD9-mH-expressing HEK293A-T-REx cell line. First, we tested the co-IP of tran-
siently-expressed PLK1-HA (Figure 2E). The co-IP of PLK1-HA was observed regardless of UV dam-
age stress in cells that expressed wild-type RAD9-mH, and was greatly diminished in cells that
expressed the T292A-mutated RAD9-mH (Figure 2E). We further confirmed the co-IP of endoge-
nous PLK1. The co-IP of PLK1 was also observed in cells that expressed wild-type RAD9-mH, but
was decreased in cells that expressed the T292A-mutated RAD9-mH (Figure 2F). Together, these
results confirmed that PLK1 specifically targets RAD9 phosphorylated (at Thr292) by CDK, and this
targeting was demonstrated to occur in vitro and possibly in vivo. In summary, the CDK-dependent
phosphorylation of Thr292 of RAD9 is expected to provide a docking site on RAD9, and to act as a
local activator for the further phosphorylation of RAD9 by PLK1.
PLK1 phosphorylates RAD9 at Thr313 and Ser326
Having established the conditions under which PLK1, but not PLK1-KR (kinase-deficient), phosphory-
lates CDK-pretreated RAD9 (Figure 3A), we sought to identify the RAD9 sites that are phosphory-
lated by PLK1. The phosphorylated bands of RAD9 were subjected to an LC-MS/MS analysis. As
shown in Figure 3B, significant amounts of pThr313 and pSer326 were detected in GST-RAD9, when
it was incubated with both CDK2-CycA2 and PLK1. pThr312 was relatively weakly detected, and its
increase upon a co-incubation with PLK1 was not as dramatic as those observed for pThr313 and
pSer326. Furthermore, the Thr313 and Ser326 residues of RAD9 are followed by hydrophobic amino
acids, and thus Thr313 and Ser326 match the previously reported PLK1 phosphorylation consensus
sequence (Nakajima et al., 2003). These results indicated that RAD9 Thr313 and Ser326 constitute
sites that are phosphorylated by PLK1.
The region around the Thr313 phosphorylation site is conserved among the vertebrate RAD9A
proteins (In this manuscript, RAD9 is used synonymously with RAD9A unless otherwise stated.) (Fig-
ure 3—figure supplement 1A). The RAD9A proteins are thought to be the mitotic paralogues of
RAD9 that diverged from an ancestral Rad9. Interestingly, the RAD9B proteins, which are paralogues
that are thought to function in testis and/or to have distinct functions (Dufault et al., 2003;
Leloup et al., 2010; Pe´rez-Castro and Freire, 2012), lack the PLK1 phosphorylation sites identified
here (Figure 3—figure supplement 1B). These observations suggested that the interaction with
CDK-PLK1 may provide the critical difference in the regulation between these RAD9 paralogues.
To further confirm the PLK1-dependent phosphorylation, we raised antibodies against pThr313-
and pSer326-containing peptides (Figure 3—figure supplement 1C). These antibodies, a-pThr313
Figure 2 continued
and a silver-stained gel is also shown (right). (B) CDK and Thr292 of RAD9 are responsible for the PLK1-RAD9 interaction. A GSH-bead pull down assay
was performed as described in (A), except that the reactions without CDK2-CyclinA2 or GST-RAD9-T292A (T292A) mutant protein were added to the
experiment. A western blot analysis was performed using a-PLK1 and a-RAD9 antibodies. (C) The Thr292-phosphorylated peptide can compete with
the RAD9-PLK1 interaction. PLK1 (4 pmol) was pre-incubated with phospho- or non-phospho-peptides (8 nmol or 0.8 nmol, Non-P: non-phosphorylated
peptide, pT292: a peptide phosphorylated on Thr292, pS291: a peptide phosphorylated on Ser291, pS291/pT292: a peptide phosphorylated on both
Ser291 and Thr292; for the pS291/pT292 peptide, only 8 nmol was tested) for 30 min at 4 ˚C, and then mixed with GST-RAD9A (3A) (30 pmol), which
was phosphorylated by CDK2-CyclinA2 (0.5 pmol) for 30 min at 30 ˚C in a 20 ml reaction. The reaction mixture was incubated with GSH-beads for 20 min
at 4 ˚C. A schematic drawing of the experiment is shown (left). A western blot analysis was performed using a-PLK1, and a silver stained gel is also
shown (right). (D) The T292 phosphorylated peptide can promote PLK1-dependent phosphorylation of RAD9. GST-RAD9-T292A (3A) (10 pmol) was
incubated with PLK1 (0.3 pmol) and non-phospho- or phospho-peptides (0.8 nmol: same peptides used in (C)), in a 20 ml reaction for 20 min at 30 ˚C. A
schematic drawing of the experiment is shown (left). A western blot using the a-RAD9 antibody is also shown (right). (E), (F) RAD9 co-
immunoprecipitates with PLK1. Lysates prepared from 293A-T-REx cells stably expressing WT or T292A-mutated RAD9-mH (RAD9-S391A/T292A
expressing cells were used for T292A) were subjected to immunoprecipitation, using a-myc antibody-coated agarose beads. Western blots were
performed using a-RAD9 and a-PLK1 antibodies on the input (Input) and immunoprecipitates (IP). Ectopically expressed PLK1-HA was used in (E) and
endogenously expressed PLK1 was detected in (F). See also Figure 2—figure supplement 1. PLK1 interacts with and phosphorylates RAD9.
DOI: https://doi.org/10.7554/eLife.29953.004
The following figure supplement is available for figure 2:
Figure supplement 1. PLK1 interacts with and phosphorylates RAD9.
DOI: https://doi.org/10.7554/eLife.29953.005
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Figure 3. PLK1 phosphorylates RAD9 on Thr 313 and Ser 326 in vivo and in vitro. (A) PLK1 phosphorylates CDK-phosphorylated RAD9. PLK1 or PLK1-KR
(K82R) (0.3 pmol) was incubated with GST-RAD9 (3A) (10 pmol; phosphorylated with the CDK complex (0.5 pmol) for 30 min at 30 ˚C), at 30 ˚C for the
indicated time points in the presence of roscovitine (10 mM). Samples were obtained and western blot analyses using a-RAD9 (GST-RAD9) and a-pT292
(pT292) antibodies were performed. (B) Top: Samples for mass spectrometry were prepared by an in vitro CDK-PLK1 kinase assay. GST-RAD9 (3A) (5 mg)
Figure 3 continued on next page
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(pT313) and a-pSer326 (pS326), detected GST-RAD9 that had been incubated with PLK1 in kinase
buffer (Figure 3—figure supplement 1D), and the western blotting signals were largely diminished
when the mutant GST-RAD9 proteins, harboring either the T313A or S326A mutation, were used as
substrates in the PLK1 kinase assay (Figure 3—figure supplement 1E). To confirm whether the
phosphorylation at Thr313 and Ser326 occurred by PLK1 binding to RAD9, through the CDK-depen-
dent phosphorylation of Thr292, the PLK1 kinase assay with GST-RAD9 was performed in the
absence or presence of CDK2-cyclinA2. As demonstrated by western blotting, the appearance of
both the pThr313 and pSer326 signals depended on the presence of CDK2-cyclinA2 (Figure 3C,
quantification in Figure 3—figure supplement 1F). Furthermore, large decreases in the pThr313
and pSer326 western blot signals were observed when GST-RAD9-T292A was used as the substrate
in the PLK1 kinase assay (Figure 3D, quantification in Figure 3—figure supplement 1F).
PLK1 phosphorylates Thr313 and Ser326 of RAD9 in vivo
Next, we confirmed the PLK1-dependent phosphorylation of Thr313 and Ser326 of RAD9 in cells.
First, to emphasize the PLK1 action on RAD9, PLK1 was ectopically expressed in asynchronously
growing HEK293A cells that harbored a CMV-tetO-RAD9-mH construct (encoding RAD9-mH con-
trolled by a doxycycline-inducible promoter) at the FRT locus. In addition, the phosphatase inhibitor
calyculin A was added to the cells, prior to harvesting. The treatment with calyculin A forces the cells
to enter into and arrest in M phase, a condition that should also activate PLK1 (Coco-Martin and
Begg, 1997; Ishihara et al., 1989). The cell lysates were subjected to IP using a-myc antibody-
coated agarose beads, and the immunoprecipitates were analyzed by western blotting. When the
western blot was probed using the antibody against pThr313, the signals were seen with the expres-
sion of PLK1 (Figure 3—figure supplement 2A, lane 2). These signals completely disappeared when
the PLK1-KR mutant was expressed and the cells were treated with the PLK1 inhibitor BI2536 (Fig-
ure 3—figure supplement 2A, lane 3). Together, these results suggested that PLK1 mediates the
phosphorylation of Thr313 of RAD9. When the blots were instead probed with the antibody against
pSer326, again the signals were detected when PLK1 was expressed, but these signals were
decreased only slightly when PLK1-KR was expressed and the cells were treated with BI2536 (Fig-
ure 3—figure supplement 2A, compare lanes 2 and 3). This suggested that Ser326 can be phos-
phorylated by kinases other than PLK1. In this experiment, we also observed that the levels of both
pThr313 and pSer326 were only slightly, if at all, decreased in the cells that expressed the RAD9-
Figure 3 continued
was incubated with CDK2-Cyclin A2 (0.5 mg), followed by an incubation with PLK1 (5 mg) in a 100 ml reaction. Phosphorylated GST-RAD9 was pulled
down using GSH-agarose beads. A 10% portion of the captured materials was subjected to SDS-PAGE and silver staining. Bottom: Mass spectrometry
analysis of the PLK1-phosphorylated GST-RAD9 (3A), excised from the bands corresponding to band 0 to band 3 at the top. The total counts of the
reliable MS/MS spectra (confidence 95%) corresponding to the peptides originating from GST-RAD9 (3A), in which Thr292 (pT292), Thr312 (pT312),
Thr313 (pT313), Ser324 (pS324), or Ser326 (pS326), was phosphorylated. (C), (D) PLK1 phosphorylates Thr313 (pT313) and Ser326 (pS326) of RAD9, when
RAD9 was pre-phosphorylated by CDK on Thr 292 (pT292). GST-RAD9 (10 pmol) was incubated with or without CDK2-CyclinA2 (0.5 pmol) prior to
incubations with different amounts of PLK1 (0, 0.3, 0.8, 2.6, 8 pmol). The western blot is shown in (C). GST-RAD9 (3A) (10 pmol) or GST-RAD9 (3A)-T292A
(10 pmol) was incubated with different amounts of PLK1 (0, 0.3, 0.8, 2.6, 8 pmol). The western blot is shown in (D). a-RAD9 (GST-RAD9), a-pT292
(pT292), a-pT313 (pT313), and a-pS326 (pS326) antibodies were used for the western blot analyses in (C) and (D). When the GST-RAD9 was incubated
with PLK1, roscovitine (10 mM) was added to inhibit the remaining CDK. (E) 293A T-REx cells stably expressing RAD9-WT-mH (WT) or RAD9-S291A/
T292A-mH (T292A) were collected, two hours after UV-irradiation (1 J/m2, 10 J/m2). To inhibit the cellular PLK1, BI2536 (2 mM) was added for 15 min,
prior to the harvest. Cell lysates were subjected to immunoprecipitation using a-myc antibody-coated agarose beads. Western blotting analyses of the
input (Input) and immunoprecipitates (IP) were performed, using a-RAD9 (RAD9), a-pT292 (pT292), a-pT313 (pT313), and a-pS326 (pS326) antibodies.
See also Figure 3—figure supplement 1. PLK1 phosphorylates RAD9 on Thr 313 and Ser 326, Figure 3—figure supplement 2. PLK1 phosphorylates
RAD9 on Thr 313 and Ser 326 in vivo and Figure 3—figure supplement 3. The phosphorylation status of RAD9 under various genotoxic stresses.
DOI: https://doi.org/10.7554/eLife.29953.006
The following figure supplements are available for figure 3:
Figure supplement 1. PLK1 phosphorylates RAD9 on Thr 313 and Ser 326.
DOI: https://doi.org/10.7554/eLife.29953.007
Figure supplement 2. PLK1 phosphorylates RAD9 on Thr 313 and Ser 326 in vivo.
DOI: https://doi.org/10.7554/eLife.29953.008
Figure supplement 3. The phosphorylation status of RAD9 under various genotoxic stresses.
DOI: https://doi.org/10.7554/eLife.29953.009
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S291A/T292A mutant (Figure 3—figure supplement 2A, lane 4), in contrast to the results obtained
in the in vitro experiment. This distinction may be due to the strong activation and over-expression
of PLK1 in calyculin A-treated cells, which may obviate the need for Thr292 phosphorylation to
locally activate PLK1 for RAD9 phosphorylation.
Next, to determine whether endogenous PLK1 could phosphorylate RAD9, we employed asyn-
chronously growing HEK293 cells harboring the CMV-tetO-RAD9-mH construct at the FRT locus.
These cells were exposed to UV irradiation, in the presence or absence of the PLK1 inhibitor BI2536,
before harvesting, and cell lysates were prepared. RAD9-mH was immunoprecipitated with a-myc
antibody-coated agarose beads, and monitored by western blotting using a-RAD9, a-pThr292, a-
pThr313, and a-pSer326 antibodies (Figure 3E). The signal recognized by a-RAD9 remained
unchanged regardless of the UV irradiation dose, BI2536 treatment, or T292A mutation. However,
the pThr292 signal, which was relatively unchanged in the UV-irradiated cells, was increased in the
BI2536-treated cells (Figure 3E, IP; lanes 5 and 6), implying that this CDK-dependent phosphoryla-
tion event (pThr292) occurred upstream of the PLK1-dependent phosphorylation. We observed
diminished pThr313 levels when the cells were treated with BI2536 (Figure 3E, lanes 5 and 6), or
when T292A-mutated RAD9 was expressed (Figure 3E, lanes 7, 8 and 9) instead of wild-type RAD9
(WT). These results indicated that the generation of pThr313 is dependent on PLK1, which (as dem-
onstrated above) is bound to and activated by pThr292 of RAD9. Interestingly, the pThr313 signal
increased slightly when the cells were UV-irradiated (Figure 3E, lanes 3 and 4). We also observed
that the pSer326 signal increased upon UV irradiation, and a slight decrease was detected when the
cells were treated with BI2536 (Figure 3E, lanes 5 and 6). However, we did not see a decrease of
pSer326 in the T292A-mutated RAD9 (Figure 3E, lanes 7, 8 and 9). Although (as shown above)
pSer326 can be phosphorylated by PLK1, we postulate that other kinases can substitute for PLK1 for
this function, permitting the phosphorylation of Ser326 without the prerequisite phosphorylation of
Thr292.
Next, we analyzed whether DNA replicative stress could also affect the PLK1-dependent phos-
phorylation of RAD9. HEK293A cells harboring the CMV-tetO-RAD9-mH construct at the FRT locus
were synchronized by a double-thymidine block, and the released cells were treated with 0.2 mM
HU. The cell lysates were subjected to IP to monitor the phosphorylation of RAD9 (Figure 3—figure
supplement 2B). Although the total amounts of (RAD9), pThr313 (pT313), and pSer 326 (pS326)
were relatively unchanged by the HU exposure, the amount of pThr292 (pT292) was somewhat
decreased. These data suggested that pThr292 efficiently triggers PLK1-dependent phosphorylation
upon UV- or HU-induced stress.
We tested the effects of other types of DNA damage on the PLK1-dependent phosphorylation of
RAD9. Treatments with camptothecin (CPT: topoI inhibitor), ionizing radiation (IR), or high doses of
methylmethanesulfonate (MMS: 0.03%) or mitomycin C (MMC: 1 mg/ml) yielded slight increases in
the pSer326 phosphorylation (Figure 3—figure supplement 3A and B). Aphidicolin (Aph: a DNA
polymerase inhibitor) treatment reduced the levels of both pThr313 and pSer 326; however,
pThr292 was also decreased, and thus these results suggested that the efficiency of PLK1-dependent
phosphorylation is either maintained or slightly enhanced in response to most types of genotoxic
stress (Figure 3—figure supplement 3).
PLK1-dependent phosphorylation of RAD9 Thr313 is required to
suppress S-phase checkpoint response
If PLK1 acts on RAD9 downstream of CDK in vivo, then the mutation of PLK1-dependent phosphory-
lation sites should affect cells in a manner similar to that seen with RAD9-T292A. We therefore con-
structed U2OS or HEK293A cell lines that encoded RAD9 with the T313A or S326A mutation, and
expressed the mutant proteins under the control of the CMV promoter from a construct located at
the FRT locus. The expression of RAD9-mH in U2OS cells is shown in Figure 4—figure supplement
1.
First, we assessed whether the PLK1-dependent phosphorylation affected the retention of the
mutated RAD9 proteins on damaged chromatin. In a fractionation assay, we observed the increased
accumulation of T313A-mutated RAD9 in the insoluble fraction upon HU treatment (Figure 4A, Tri-
ton-X insoluble, +HU). We also observed the accumulation of Ser345-phosphorylated CHK1 in the
insoluble fraction of HU-treated cells that expressed the T313A-mutated RAD9 (Figure 4A, Triton-X
insoluble, +HU). It should be noted that lower levels of the S326A-mutated RAD9 accumulated in
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Figure 4. Enhanced checkpoint signaling when PLK1 fails to phosphorylate RAD9. (A) A chromatin fractionation assay (see Materials and methods) was
performed in HEK293A-T-REx cell lines stably expressing RAD9-WT-mH (RAD9-WT), RAD9- T313A-mH (RAD9-T313A) or RAD9- S326A-mH (RAD9-
S326A). Cells were grown in media containing 0.2 mM hydroxyurea for 24 hr (+HU). A western blotting analysis is shown. a-TopBP1, a-CLASPIN, a-myc
(RAD9-myc), a-phospho-serine 345 of CHK1 (CHK1-pS345), a-CHK1, a-phospho-serine 139 of Histone H2AX (p-H2AX), a-H2AX, and a-tubulin were
used. (B) The incorporation of ethynyl-deoxy-uridine (EdU) was quantified in U2OS cells stably expressing RAD9-WT-mH (WT), RAD9-S291A/T292A-mH
(T292A), RAD9-T313A-mH (T313A) or RAD9-S326A-mH (S326A) from the FRT locus (see Materials and methods). The cells were incubated with 5 mM of
EdU before the harvest (30 min for cells without hydroxyurea treatment, 1 hr for cells with 0.2 mM hydroxyurea). The samples were stained with Alexa
Fluor 488 azide using the Click reaction, and subjected to the flow cytometry analysis. An example of the data is shown in Figure 4—figure
supplement 3. The incorporated signals were quantified, and the mean values from three independent experiments are plotted. See also Figure 4—
figure supplement 1. U2OS stable cell line that expresses RAD9-mycHis, Figure 4—figure supplement 2. DNA damage signaling was increased when
PLK1 failed to phosphorylate RAD9, Figure 4—figure supplement 3. dNTP incorporation was decreased in HU treated cells where PLK1-dependent
phosphorylation on RAD9 was defective, Figure 4—figure supplement 4. The analysis using the CMV-RAD9-expressing U2OS cell line under
endogenous RAD9 knock down, Figure 4—figure supplement 5. Decreased dNTP incorporation was observed in telomerase-positive HEK293A cells
that expressed CDK-PLK1-dependent phosphorylation defective RAD9 and Figure 4—figure supplement 6. EdU incorporation assay under
Aphidicolin- and MMC-induced stress.
DOI: https://doi.org/10.7554/eLife.29953.010
The following figure supplements are available for figure 4:
Figure supplement 1. U2OS stable cell line that expresses RAD9-mycHis.
DOI: https://doi.org/10.7554/eLife.29953.011
Figure supplement 2. DNA damage signaling was increased when PLK1 failed to phosphorylate RAD9.
DOI: https://doi.org/10.7554/eLife.29953.012
Figure supplement 3. dNTP incorporation was decreased in HU treated cells in which PLK1-dependent phosphorylation of RAD9 was defective.
DOI: https://doi.org/10.7554/eLife.29953.013
Figure supplement 4. The analysis using CMV-RAD9-expressing U2OS cell line under endogenous RAD9 knock down.
DOI: https://doi.org/10.7554/eLife.29953.014
Figure supplement 5. Decreased dNTP incorporation was observed in telomerase-positive HEK293A cells that expressed CDK-PLK1-dependent
phosphorylation defective RAD9.
DOI: https://doi.org/10.7554/eLife.29953.015
Figure supplement 6. EdU incorporation assay under Aphidicolin- and MMC-induced stress.
DOI: https://doi.org/10.7554/eLife.29953.016
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the insoluble fraction (compared to the accumulation of RAD9-T313A under the same conditions).
These results indicated that the PLK1-dependent phosphorylation of the Thr313 residue of RAD9
phenocopies the T292A-mutated RAD9, and suggested that PLK1 acts downstream of CDK to con-
trol the dissociation of RAD9 from chromatin upon genotoxic stress. Consistent with this interpreta-
tion, we also observed that the inhibition of the PLK1 activity by BI2536 also caused the
accumulation of endogenous RAD9 in the insoluble fraction, when the cells were treated with HU
(Figure 4—figure supplement 2). Since both TopBP1 and CLASPIN, which act as mediators for
checkpoint signaling, also accumulated in the insoluble fraction upon the inhibition of PLK1 in HU-
treated cells, we concluded that a PLK1-dependent phosphorylation event controls the association
of the checkpoint machinery with chromatin.
Next, we analyzed whether the PLK1-dependent phosphorylation (pThr313) of RAD9 follows the
CDK-dependent phosphorylation (pThr292), in terms of controlling the rate of DNA replication. To
do so, we quantitated the rate of dNTP incorporation in the U2OS cells. The cells that expressed the
T313A- or S326A-mutated RAD9 were exposed to 0.2 mM HU for 24 hr, and then to EdU for 1 hr
prior to harvest. The incorporated EdU was fluorescently labeled by the click reaction, and the cells
were subjected to a flow cytometric analysis. The cells that expressed the T313A-mutated RAD9
showed a significantly lower level of EdU incorporation, as compared to the cells that expressed
wild-type RAD9 (as seen in T292A-RAD9 expressing cells) (Figure 4B, Figure 4—figure supplement
3). The cells that expressed the S326A-mutated RAD9 and those expressing wild-type RAD9 incor-
porated similar levels of EdU. These results suggested that pThr313, as well as pThr292, of RAD9 is
responsible for maintaining the rate of DNA replication upon genotoxic stress. Together, these
experiments indicated that the CDK-PLK1 axis targets RAD9 to antagonize the checkpoint response
upon replicative stress.
We also knocked down the endogenous RAD9 (Figure 4—figure supplement 4A), to determine
whether the cellular effect observed upon the expression of the T313A- or S326A-mutated RAD9 is
enhanced. In cells that expressed the T313A-mutated RAD9, the transfection of siRAD9 yielded an
enhancement in the phosphorylation of Ser345 of CHK1 (Figure 4—figure supplement 4B) and a
slight reduction in the rate of DNA replication upon HU treatment, as compared to cells that were
not treated with siRAD9 (Figure 4—figure supplement 4C). These results indicated that, although
the expression of RAD9 under the control of the CMV promoter was sufficient to confer the pheno-
type, the knockdown of the endogenous RAD9 could enhance the cellular effect to a certain extent.
In cells that expressed the S326A-mutated RAD9, the silencing did not result in an obvious enhance-
ment of the phosphorylation of Ser345 of CHK1 or a decrease in the DNA replication rate (Fig-
ure 4—figure supplement 4D,E). Furthermore, we also confirmed the reduction in the DNA
replication rate in telomerase-positive HEK293A cells (Bryan et al., 1995) expressing either T292A-
or T313A-mutated RAD9 (Figure 4—figure supplement 5A and B). This result excluded the possi-
bility that the slowing of the DNA replication rate was caused by an atypical mechanism for check-
point control, which may occur in U2OS cells via Alternative Lengthening of Telomeres (ALT)
(Figure 4—figure supplement 5A and B).
A slower DNA replication rate was also observed in response to other types of DNA damage.
Specifically, aphidicolin treatment also reduced the rate of EdU incorporation, and MMC treatment
caused more cells to accumulate in early S phase when the T313A-mutated RAD9 was expressed,
although the latter treatment did not yield an obvious decrease in the EdU incorporation (Figure 4—
figure supplement 6). The observed phenotype may have been specific to the direct inhibition of
DNA replication by some agents (HU, a dNTP synthesis inhibitor; aphidicolin, a DNA polymerase
inhibitor), but not by others (MMC, a DNA damaging agent that crosslinks DNA strands).
We next performed a DNA combing assay, to determine which steps of DNA replication contrib-
ute to slowing down bulk DNA synthesis. The DNA damage checkpoint involves controlling either
the dormant/late replication origin firing or the velocity of individual replication forks. The DNA
combing technique allows the measurement of individual replication fork rates, and of the IOD
(Inter-Origin Distance) values that may reflect the efficiency of dormant origin firings. At the end of
the HU treatment, the WT- or T313A-mutated-RAD9 expressing U2OS cells were pulse-labeled by 5-
iodo-2’-deoxyuridine (IdU), preceded by 5-chloro-2’-deoxyuridine (CldU) (Figure 5A). The DNA syn-
thesis on DNA fibers was visualized (Figure 5B), and the IOD values and the fork velocities were
measured (Figure 5C,D,E). In the absence of HU, the rates of individual replication forks in cells that
expressed RAD9-WT were 0.85 ± 0.36 kb/minutes, and those of the RAD9-T313A expressing cells
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were slower (0.66 ± 0.27 kb/minutes, p-value: 5.8  10 7). The IOD values were 131 ± 62 kb in
RAD9-WT expressing cells, and 107 ± 61 kb in RAD9-T313A expressing cells. This shorter IOD dis-
tance in Rad9-T313A expressing cells implied a higher efficiency of origin firing, which could result in
a similar rate of bulk DNA synthesis to that seen in RAD9-WT expressing cells under non-stressed
conditions. We then measured the fork rates under the HU stress, and observed that the rates of the
DNA replication forks became slower in both RAD9-WT and RAD9-T313A expressing cells, with





















































































































































Figure 5. The effect of origin firing and DNA replication fork integrity of PLK1-dependent phosphorylation on RAD9. (A) A schematic of the time course
applied for the combing assay analysis. U2OS cells expressing WT- or T313A-RAD9 from genomic FRT sites were used for the analysis. (B) Examples of
DNA fibers seen in the DNA combing assay. The vertical strips seen were either the boundary of the assembled photo frames or noise produced upon
scanning of DNA fibers. See the supplement for the surrounding regions (Supplementary file 3). (C) A schematic of the measurement of replication
fork velocity. A green signal (IdU labeled DNA) was measured on a unidirectionally moving fork that is associated with a red signal (CldU labeled DNA).
(D), (E) Mean Inter Origin Distance (IOD) values were measured and plotted on the graph in (D) (WT no HU: n = 140, T313A no HU: n = 146, WT 0.2 mM
HU: n = 231, T313A 0.2 mM HU: n = 229). The velocity of each DNA replication fork was measured and plotted in (E). Boxplots overlaid with beeswarm
plots are shown. Boxes indicate the upper and lower quartiles, and the central bar indicates the median value of the measurements. The graphs were
made with the R program. The p-values in the IOD analysis were 8  10 8 (without HU) and 0.058 (with HU) (WT vs. T313A; the measurement values
that were statistically significant (within the top and bottom whisker bars) were applied to calculate the p-values). The p-value in the replication fork
velocity analysis was 5.8  10 7 (WT vs. T313A, without HU). See also Figure 5—figure supplement 1. The DNA combing assay in aphidicolin-treated
cells, Figure 5—figure supplement 2. Enhanced RAD9-CLASPIN complex formation when CDK or PLK1 failed to phosphorylate RAD9.
DOI: https://doi.org/10.7554/eLife.29953.017
The following figure supplements are available for figure 5:
Figure supplement 1. The DNA combing assay in aphidicolin-treated cells.
DOI: https://doi.org/10.7554/eLife.29953.018
Figure supplement 2. Enhanced RAD9-CLASPIN complex formation when CDK or PLK1 failed to phosphorylate RAD9.
DOI: https://doi.org/10.7554/eLife.29953.019
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similar velocities (WT: 0.37 ± 0.16 kb/minutes, T313A: 0.37 ± 0.19 kb/minutes). Under these condi-
tions, the IOD of the RAD9-T313A expressing cells was slightly longer than that of RAD9-WT
expressing cells (WT: 61 ± 38 kb, T313A: 69 ± 41 kb), although the difference is marginally significant
(p-value: 0.058).
The replication fork velocities under non-stressed and stressed conditions were confirmed in an
independent combing assay. Samples for either non-treated or aphidicolin-treated (0.4 mM) cells
(RAD9-WT and -T313A expressing cells) were applied. A slower replication fork progression rate was
observed in the non-treated RAD9-T313A expressing cells (Figure 5—figure supplement 1), consis-
tent with the data obtained in the former assay (Figure 5), although the absolute values of the fork
progression rate were smaller under the latter conditions, perhaps due to the different method used
to prepare the fibers on the slides (see Materials and methods). When the cells were treated with
aphidicolin, the replication fork rate was similar to that under the conditions with 0.2 mM HU, again
suggesting that the fork progression rate did not cause the difference in the slow S-phase progres-
sion rate. In summary, we concluded that the reason for the slower rate of S-phase progression is
not due to the reduction of the replication fork rate in the RAD9-T313A expressing cells. Further
analysis is needed to determine whether the increase in the distance between firing origins contrib-
utes to the slow S-phase. It should also be noted that the replication fork rate was already slower in
the RAD9-T313A expressing cells under non-stressed conditions, which may suggest that the check-
point response is enhanced in the RAD9-T313A expressing cells in the normal cell cycle (see
discussion).
Finally, we observed that the T292A- or T313A-mutated RAD9 co-immunoprecipitated with
increased amounts of CLASPIN upon HU treatment ((Figure 5—figure supplement 2), see ‘HU’ in
IP). Together, these results suggested that the S-phase checkpoint response is enhanced when PLK1
fails to phosphorylate RAD9.
CDK- and PLK1-dependent phosphorylation of RAD9 allows cells to
grow under genotoxic stress
If the collaboration of CDK and PLK1 in phosphorylating RAD9 is required for decreasing RAD9’s
S-phase checkpoint function, then cells expressing the T292A- or T313A-mutated RAD9 should be
growth-compromised under genotoxic stress. Indeed, we observed that cells expressing the T292A-
or T313A-mutated RAD9 exhibited a slower growth rate in the presence of HU (For U2OS cells,
Figure 6A; for HEK293A cells, Figure 6—figure supplement 1). Additionally, as compared to the
cells that expressed wild-type RAD9, the cells that expressed T313A-mutated RAD9 exhibited a sig-
nificant decrease in colony-forming efficiency (as assessed by a cell viability assay) upon exposure to
0.2 mM HU (Figure 6B). Together, these results imply a role for the CDK- and PLK1-dependent
phosphorylation of RAD9 in facilitating growth under genotoxic stress.
Discussion
Cells must overcome environmental stresses that have the potential to disturb their proliferation. In
the case of genotoxic stress, DNA damage checkpoints are activated to restore cellular viability.
However, such checkpoints can also serve as anti-proliferation signals. Thus, the proliferation status
of cells must be coupled to the activities of the checkpoint machineries. Here, we demonstrated the
collaborative action of CDK and PLK1 in phosphorylating the checkpoint protein RAD9, thereby min-
imizing RAD9’s checkpoint activating function to maintain the rate of S-phase, and in turn to main-
tain the higher cellular growth rate (Figure 7). The CDK- and PLK1-dependent phosphorylation of
RAD9 reduces the binding of RAD9 to damaged chromatin, suggesting the dynamic control of active
checkpoint complexes at DNA damage sites to regulate the degree of DNA damage checkpoint sig-
naling. Our results have elucidated the mechanism by which the cell cycle status controls the DNA
damage sensor complex to ensure proliferation under genotoxic stress, thus improving our under-
standing of the balance between anti- and pro-proliferation signals.
CDK and PLK1 target RAD9 to modulate DNA damage detection
When cells that were defective in the CDK- or PLK1-dependent phosphorylation of RAD9 (demon-
strated by the expression of T292A- or T313A-mutated RAD9) were grown under replicative stress
(0.2 mM HU), more cells accumulated in S phase, and the incorporation of dNTPs during S phase
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was greatly decreased, as compared to that observed in cells expressing wild-type RAD9. These
results suggested that CDK plays a role in maintaining a high rate of S-phase progression, via the
facilitation of the PLK1-dependent phosphorylation of RAD9.
The region where CDK phosphorylates RAD9 (on Thr292) has a typical consensus sequence for a
PBD binding site (van Vugt et al., 2010). Using a peptide competition assay, we showed that PLK1
bound RAD9 phosphorylated at Thr292. Furthermore a peptide phosphorylated on Thr292 activated
PLK1. Since PBD acts as an auto-inhibitory domain, with inhibitory activity relieved when the domain
is bound to a substrate (Xu et al., 2013), we concluded that RAD9 phosphorylated on Thr292 pro-
vides a genuine binding site for PLK1.
The interaction between a PBD and the phospho-peptide is reportedly strong, with a dissociation
constant in the range of a few hundred nanomolar (van Vugt et al., 2010). This high affinity may
allow a minimal amount of PLK1 to target the Thr292-phosphorylated RAD9, and would suit binding
by PLK1, which exhibits rather repressed expression during interphase (Winkles and Alberts, 2005).
In this scenario, once Thr292 is phosphorylated, PLK1 easily targets and binds RAD9, leading to the
local activation of PLK1 and the phosphorylation of the Thr313 residue of RAD9.
What is the molecular impact of the PLK1-dependent phosphorylation of RAD9? RAD9, as a com-
ponent of the PCNA-like 9-1-1 complex, is loaded onto 5’ recessed DNA ends at damage sites, and
also accommodates TopBP1 and CLASPIN to facilitate signaling through checkpoint kinases
(Delacroix et al., 2007; Furuya et al., 2004; Kumagai et al., 2006; Lee et al., 2007; Liu et al.,
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Figure 6. PLK1-dependent phosphorylation of RAD9 is required for proliferation under replicative stress. (A) Cell growth was monitored using the
Presto-Blue Cell viability reagent (see Materials and methods). U2OS cells stably expressing RAD9-WT-mH (WT), RAD9-S291A/T292A-mH (T292A), and
RAD9-T313A-mH (T313A) from the FRT locus, and the host U2OS T-REx cells (Mock) were used. (B) The cellular viability in the presence of hydroxyurea
was monitored by a colony formation assay (see Materials and methods). U2OS cells stably expressing RAD9-WT-mH (RAD9-WT) and RAD9-T313A-mH
(RAD9-T313A) from the FRT locus, and the host U2OS T-REx cells (Mock) were used. See also Figure 6—figure supplement 1. Reduced cell
proliferation by expression of non-phosphorylatable RAD9 in telomerase-positive HEK293A cells.
DOI: https://doi.org/10.7554/eLife.29953.020
The following figure supplement is available for figure 6:
Figure supplement 1. Reduced cell proliferation by expression of non-phosphorylatable RAD9 in telomerase-positive HEK293A cells.
DOI: https://doi.org/10.7554/eLife.29953.021
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that RAD9’s function as a DNA damage sensor is the target of PLK1-dependent regulation, given
that we observed increased amounts of RAD9 on the chromatin when PLK1 failed to phosphorylate
RAD9. The PLK1-dependent phosphorylation of RAD9 would minimize the amount of RAD9 bound
at sites of stalled replication forks or replicative DNA damage, possibly by giving dynamism to the
9-1-1 complex from the DNA ends, and may in turn reduce the number of active checkpoint com-
plexes. In RAD9, the sites of PLK1-dependent phosphorylation are located within the tail region.
This region of RAD9 is expected to help the protein associate with DNA damage sites. For example,
the region phosphorylated by PLK1 is close to the region required for the association with the sin-
gle-stranded-DNA binding protein RP-A (Figure 3—figure supplement 1A)(Xu et al., 2008). Fur-
thermore, we did not observe a decrease in the amount of the RAD9-bound clamp-loader RAD17 in
the co-IP experiment when T292 was mutated, even under genotoxic stress conditions (data not
shown). Thus, the PLK1-dependent phosphorylation may affect the affinity of the 9-1-1 complex itself
to the DNA damage sites. This regulation is influenced by the balance between the cellular pro-
mitotic activity and the DNA damage checkpoint activity, which may be determined by the amounts
of PLK1, the CDK activity, and the degree of DNA damage stress. In other words, the cellular prolif-
eration status may influence the cell’s ability to detect DNA damage during checkpoint activation.
Phosphorylation of the checkpoint sensor protein by CDK and PLK1 is
required for maintaining the rate of DNA replication upon genotoxic
stress
In eukaryotic cells, the rate of S-phase progression is related to the number of available replication
origins (Yekezare et al., 2013). Upon growth under genotoxic stress, the replication rate can be





































Figure 7. A schematic of PLK1-dependent damage tolerance. (Left) The collaboration of CDK and PLK1 targets and suppresses the DNA damage
detection machinery in the DNA damage checkpoint process, and promotes the S-phase progression to support cell proliferation. (Right) When CDK
and PLK1 fail to phosphorylate RAD9 (in the case of the PLK1 inhibitor, RAD9-T292A or -T313A mutant expressing cells), DNA damage checkpoint
activation is increased and confers the slow growth.
DOI: https://doi.org/10.7554/eLife.29953.022
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of the late-replication origins (Santocanale and Diffley, 1998; Shirahige et al., 1998). This inhibition
of origin firing might prevent the generation of additional replicative stress in un-replicated regions
of the genome, and would suppress genomic instability (Boos et al., 2011; Petermann et al., 2010;
Yekezare et al., 2013). Alternatively, the slow S phase progression rate could be caused by the
reduction in the progression rate of individual replication forks, which is reportedly dependent on
CHK1 activation upon camptothecin-induced stress, and may allow the fork to mount a more robust
response to the damage (Iyer and Rhind, 2013; Seiler et al., 2007). It has also been proposed that
the reduction of the fork speed results in the activation of dormant origins proximal to the stalled
replication fork, a process that may compensate for decreases in the local rate of DNA replication
(Yekezare et al., 2013).
The DNA fiber/combing assay under the HU treated conditions revealed that the velocities of the
replication forks were the same between the WT- and T313A-RAD9 expressing cells. This could indi-
cate that the slower S-phase progression seen in the T313A-mutated cells was not caused by the
slower velocity of the DNA replication forks. We observed a slight increase in the IOD value in the
T313A-RAD9 expressing cells, which implies the inefficient firing of dormant origins in these cells.
However, its marginal significance (p-value=0.058; WT vs. T313A) may indicate another reason, such
as the contribution of the inhibition of late origin firing to the slower progression of S-phase in
T313A-expressing cells under HU-induced stress. Perhaps more significantly, even under non-
stressed conditions, we observed a slower DNA replication fork velocity in the T313A-RAD9 express-
ing cells, as compared to that in WT-RAD9 expressing cells. This could indicate that a moderate acti-
vation of the S-phase checkpoint exists even in the normal cell cycle process in the T313A-RAD9
expressing U2OS cells. In this case, the efficient firing of dormant origins may compensate for the
overall S-phase rate; however, a more detailed analysis (e.g., shorter pulse-label duration) should be
performed to arrive at a definite conclusion. In the T313A-expressing cells, further exposure to HU-
induced stress would activate an excessive DNA damage response and could cause a reduction in
the number of firing origins, which would result in a slower rate of S-phase progression. In this sce-
nario, PLK1 may raise the threshold of the DNA damage level, which would require more DNA dam-
age stress for the checkpoint activation during S-phase. In other words, the PLK1-dependent
phosphorylation of RAD9 may suppress the activation step of the checkpoint, rather than diminish-
ing the activated DNA damage checkpoint processes, and this process could act as a novel DNA
damage tolerance mechanism to facilitate cell proliferation. The dynamics between the proliferation
control and the DNA damage sensors at DNA damage sites should be clarified in the future, to facil-
itate our understanding of the ability of cells to drive proliferation under environmental stresses.
PLK1 mediates tolerance to genotoxic stress
PLK1 is a pro-mitotic kinase, and its main function is to facilitate the mitotic process. However, PLK1
also functions in DNA metabolism, and probably coordinates cellular proliferation and genomic sta-
bility. In addition to its role in antagonizing the DNA damage checkpoint activity, PLK1 reportedly
promotes DNA replication by phosphorylating Orc2, an event that may be critical to maintain geno-
mic DNA replication under replicative stress (Song et al., 2011). The PLK1-mediated phosphoryla-
tion of Ser188 of Orc2 is responsible for the resistance of pancreatic tumor cells to the
chemotherapy drug gemcitabine, an agent that inhibits DNA replication (Song et al., 2013). This
phosphorylation event probably stabilizes the pre-replicative complexes to ensure that the cells con-
tinue to progress through S phase despite the genotoxic stress, possibly by keeping dormant origins
active (Song et al., 2013). Combined with our finding of the PLK1-dependent phosphorylation of
RAD9, these results suggest that PLK1 employs multiple targets to drive S-phase progression in cells
under stress, thus facilitating tolerance to genotoxic stresses.
For cancer cells, counteracting these checkpoint-related processes is expected to be a favorable
tactic for driving cellular proliferation. Indeed, the ectopic expression of PLK1 is associated with a
wide range of tumor types. PLK1 is also known to be involved in promoting resistance to chemother-
apeutic regimens with drugs such as doxorubicin (a DNA intercalating compound) or gemcitabine (a
DNA analogue that serves as an inhibitor of DNA replication) (Gutteridge et al., 2016). Thus, an
improved understanding of DNA-related metabolism involving PLK1 will be met with keen interest,
as such information could facilitate the effective use of PLK1 inhibitors during cancer therapies.
In summary, we demonstrated that CDK and PLK1 target the DNA damage sensor RAD9 to mini-
mize the checkpoint response, and revealed an underlying mechanism whereby cells can tolerate
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genotoxic stress and proceed with proliferation. Thus, a complex balancing mechanism exists to
coordinate proliferation and the stress response, and more systematic investigations of this mecha-
nism should be conducted in the future.
Materials and methods
Plasmids and primers
The RAD9A cDNA was purchased from OriGene. The gene encoding C-terminally myc-His6 (mH)-
tagged RAD9 was constructed in pCDNA3.1 or pCDNA5/FRT. The cloned RAD9 was mutagenized
for siRAD9 (s11719: Ambion) resistance. The mutations in RAD9 were introduced using KOD poly-
merase (TOYOBO, Japan) and mutagenized primers. The primers used to mutagenize RAD9 are pre-
sented in the supplementary table (Supplementary file 1). The primers to construct the resistant
RAD9 against siRAD9 (s11719: Ambion) were #2147/#2150, and are also included in
Supplementary file 1. The gene encoding GST-tagged RAD9 used for bacterial expression was con-
structed on the pGEX-6P plasmid. Primers #1663/#1664 (Supplementary file 1) were used for the
subcloning. For the two-hybrid assay, a pLex-A fusion system and pACT2 (or pGADT7) were used to
construct the bait and prey plasmids, respectively (Bartel and Fields, 1995; Tanaka et al., 2013).
The regions encoding the polo-box domains of PLK1-5 were amplified from a cDNA library (a kind
gift from Dr. Seiji Tanaka, Kochi University of Technology), using the primers listed in
Supplementary file 1. Other plasmids used to express the PLK1, pCDNA-flag-PLK1 and pGEX-6P-
PLK1 (wt and K82R) proteins were kind gifts from Dr. M. Osugi (Tokyo University). For the expression
of the active CDK protein, the plasmid that expresses the CIV1 (CAK in S. cerevisiae), CDK2, and
Cyclin E proteins, controlled by a dual promoter system, was provided by Dr. Tatsuro Takahashi
(Kyushu University), and the plasmid that expresses the active CDK2-CyclinA2 protein is a derivative
of that plasmid.
Cell culture and transfection
HEK293A cells (purchased from Invitrogen) and HEK293A T-REx cells were cultured in Dulbecco’s
modified Eagle’s medium, supplemented with 10% fetal bovine serum. U2OS cells (purchased from
IDAC, Tohoku University) and U2OS T-REx cells were cultured in RPMI medium, supplemented with
10% fetal bovine serum. Cell lines used were exposed to plasmocin to avoid possible contamination
of mycoplasma and tested for the TAKARA PCR mycoplasma kit. Plasmid transfection was per-
formed using the Attracten transfection reagent, according to the manufacturer’s protocol (Qiagen).
For the induction from the tetO-harboring plasmid, doxycyclin (0.5 mg/ml) was used. For the knock-
down of RAD9, siRAD9 (Ambion: s11719) was used. The transfection of the siRNA was performed
using the Dharmafect one transfection reagent, according to the manufacturer’s protocol (Dharma-
con). The control siRNA was purchased from QIAGEN. To inhibit cellular kinases, a PLK1 inhibitor
(BI2536: AdooQ Bioscience, USA) and a CDK2 inhibitor (RO-3306: Santa Cruz, USA) were used. To
perturb cell cycle progression, hydroxyurea (Sigma-Aldrich) was used. For the double thymidine
block, first, 2.5 mM thymidine was added to the media, followed by 10 hr of incubation without thy-
midine. Then, a second thymidine block was performed for 20 hr before the release.
Cell growth or viability assay
To monitor cell growth, the Presto-Blue Cell Viability Reagent (Thermo Fisher) was used according
to the manufacturer’s protocol. Briefly, 1  104 cells / 150 ml / well of U2OS cells that stably express
the RAD9 gene were cultured in 96-well dishes with hydroxyurea. Every 24 hr, the 96 well dish was
monitored for cell growth. Presto-Blue (17 ml) was added to each well, followed by an incubation in a
CO2 incubator at 37 ˚C for 10 min. Subsequently, 75 ml of 10% SDS was added to stop the reaction,
and the plate was placed in an ARVO-X3 plate reader (Perkin Elmer). A 531 nm excitation filter and
a 616 nm emission filter were used, and for each cell line and hydroxyurea condition, triplicate sam-
ples were measured and the average values were plotted in the graph. To monitor the cell viability
upon hydroxyurea exposure, a colony formation assay was performed. First, U2OS cells that express
the RAD9 protein were treated with 0.2 mM hydroxyurea for 36 hr. The cells were collected by tryp-
sinization, and 500 cells / 10 ml were plated onto 10 cm dishes, followed by an incubation at 37 ˚C in
a CO2 incubator for 11 days. The plates were stained with crystal violet/methanol.
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Antibodies and western blotting
Western blot analyses were performed with anti-g-H2AX (Millipore), anti-H2AX (Sigma-Aldrich), anti-
RAD9 (Santa Cruz or Bethyl), anti-RAD17, anti-RAD1, anti-TopBP1, anti-CLASPIN (Santa Cruz), anti-
tubulin, anti-CHK1, anti-CHK1-pS345, and anti-CHK2-pT68 (Cell Signaling Technology) antibodies.
The antibodies against the phospho-peptides (pThr292: LQAHSpTPHPDC, pThr313: CAMETp-
TIGNEG, pSer326: CEGSRVLPSIpS) were raised by MBL (Medical and Biological Laboratories (MBL),
Japan). HRP-conjugated antibodies were used as secondary antibodies, the ECL signal was incorpo-
rated using a Licor Odyssey Fc imager system, and the quantification was performed with the Image
Studio software.
Flow cytometry and EdU incorporation assay
To measure the incorporation rate of deoxyribonucleotides, the amount of incorporated EdU in cells
was measured by a flow cytometer using the reported labeling protocol (Jia et al., 2015). Cells were
incubated with 5 mM of EdU (for the non-stressed cells: 30 min, for the HU-stressed cells: 60 min)
before fixation by formalin (3.7%) for 10 min on ice. The PBS-washed cells were subjected to metha-
nol fixation. The fixed cells were washed twice with PBS-Triton X-100 (0.1%), and subjected to the
Click reaction for one hour at room temperature. The reaction mixture included 20 mM Tris (pH 7.4),
1/1,000 Alexa Fluor 488-azide (Molecular Probes), 0.1% CuSO4, and 1 mg/ml of ascorbate. The
labeled cells were washed with PBS-Triton X-100 and treated with a PI/RNaseA solution for 30 min,
followed by a wash with PBS-Triton X-100. The cell cycle and the fluorescently labeled EdU were
measured using a Guava easyCyte (Millipore) or FACSCalibur flow cytometer.
In vitro assays
The proteins were purified through GSH-beads (4 ˚C, 1 hr in TEG buffer (Tris-Cl, pH 7.5, 50 mM,
NaCl 150 mM, EDTA-Na 10 mM, glycerol 10%, Triton X-100 0.5–1%)). The GST-RAD9 proteins were
eluted by 10 mM of glutathione (15 min, 3 times), and the CDK complex and PLK1 proteins were
eluted by PreScission Protease (GE Healthcare, 15 min, 3 times). After the elution of the CDK com-
plex and PLK1, the proteins were further incubated with GSH-beads to eliminate the residual GST-
tagged proteins. All of the purified proteins were subjected to dialysis in 50% glycerol, 10 mM Tris-
Cl (pH 8.0). The in vitro kinase assay using the recombinant active CDK complex or PLK1 was per-
formed in kinase buffer (50 mM HEPES, pH 7.4, 10 mM MgCl2, 1 mM DTT) supplemented with 1
mM ATP. The GSH pull down assay using GST-RAD9 was performed in kinase buffer supplemented
with 0.1% Triton X-100.
Immunoprecipitation
Cell lysates were prepared in HEPES-based buffer (20 mM HEPES, pH 7.4, 150 mM NaCl, 10% glyc-
erol, 0.1 % NP40, 0.1% Triton X-100, 1 mM DTT, 0.5 mM PMSF). The lysates were sonicated and the
soluble fractions were quantified using a protein assay kit (Bio-Rad), and adjusted to 2 mg/ml. The
immunoprecipitation was performed using a c-Myc tagged Mild Purification Kit (MBL).
Yeast two-hybrid assay
To quantify the beta-galactosidase activity, an ONPG (SIGMA-Aldrich) assay was performed, accord-
ing to the Yeast Protocol Handbook (Clontech).
Liquid chromatography-tandem mass spectrometry (LC-MS/MS)
Coomassie Brilliant Blue-stained protein bands were excised from the polyacrylamide gel and sub-
jected to in-gel tryptic digestion. The digestion was performed using an In-Gel Tryptic Digestion Kit
(Thermo Fisher Scientific, Waltham, MA), according to the manufacturer’s instructions. The digestion
products were reconstituted in 0.1% formic acid and injected for separation into a NanoLC-Ultra 2D-
plus HPLC equipped with a cHiPLC Nanoflex system (Eksigent, Dublin, CA), which was used in the
trap and elute mode with a trap column (200 mm x 0.5 mm, ChromXP, C18-CL, 3 mm, 120 A˚, Eksi-
gent) and an analytical column (ChromXP, C18-CL, 3 mm, 120 A˚, Eksigent). The separation was per-
formed with a binary gradient of solvent A (98% water, 2% acetonitrile, 0.1% formic acid) and
solvent B (20% water, 80% acetonitrile, 0.1% formic acid). The gradient program was 2% to 40% sol-
vent B for 125 min, 90% solvent B for 5 min, and 2% solvent B for 19 min, at a flow rate of 300 nL/
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min. The eluates from the Nano-LC system were infused on-line to the TripleTOF 5600 + mass spec-
trometry system (SCIEX, Framingham, MA) equipped with a NanoSpray III ion source and a heated
interface. The data sets were acquired with the information-dependent acquisition method.
Identification of the phosphorylated peptides and quantitative
estimation of the specific phosphorylation
The identification of the phosphorylated peptides was accomplished using the ProteinPilot software
(version 4.5 Beta, SCIEX). The database was UniProtKB/Swiss-Prot (June 2014, Human), appended
with a known contaminant database (SCIEX) and the GST-Rad9C fusion protein sequence. The spe-
cial factors were gel-based ID and phosphorylation emphasis. Biological modifications were taken
into account. The quantitative estimation of the specific phosphorylation was performed by the spec-
tral counting method. The number of reliable MS/MS spectra (confidence 95%) corresponding to
the peptide groups derived from the GST-Rad9 C-terminus, which had phosphorylation on the same
site, irrespective of the other co-existing post-transcriptional modifications, were counted in each
group and used for the quantitative estimation.
DNA molecular combing assay
The DNA fiber assay was performed as described (Conti et al., 2007; Kuriya et al., 2015;
Michalet et al., 1997). Briefly, cells were labeled with 100 mM of IdU or CldU for 30 min and har-
vested by trypsinization. The harvested cells were embedded in agarose plugs and treated overnight
with proteinase K (2 mg/ml) in ESP buffer (1% N-L-sarcosyl in 0.5 M EDTA). The prepared samples
were subjected to DNA fiber assays to monitor the DNA replication fork rate (stretching factor upon
combing was 1.95 kb/mm). For the DNA combing assay to monitor the Inter-Origin-Distance, the
samples were sent to GENOMIC VISION (France) for the analysis. The samples were prepared as
advised, and two slides per sample were analyzed (stretching factor upon combing is approx. 2 kb/m
m). The Inter-Origin-Distance was calculated using Fiber Studio (GENOMIC VISION). We noticed
that the values of the replication fork tracks were longer in the samples obtained from GENOMIC
VISION. These were partly caused by the difference in the buffer or glass that was used to stretch
the DNA fibers. Thus, we emphasize the relative differences in values within the samples obtained
from same series of experimental preparations.
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